Fig. 1From: Prevalence and influence of hypouricemia on cardiovascular diseases in patients with rheumatoid arthritisThe levels of SUA and the prevalence of hypouricemia and hyperuricemia in RA patients with different stratification. The SUA levels in all, male, premenopausal and postmenopausal female RA patients A; The prevalence of hypouricemia and hyperuricemia in different gender B and treatment groups C; The prevalence of hyperuricemia in different age D, disease duration E, disease activity groups F; The prevalence of hypouricemia in different age G, disease duration H, disease activity groups I. *P < 0.05; **P < 0.01; ***P < 0.001. △Treatment naïve, without previous corticosteroids or disease-modifying anti-rheumatic drugs treatment for 6 months before recruited. RA rheumatoid arthritis; Remission (CDAI ≤ 2.8), LDA low disease activity (2.8 < CDAI ≤ 10), MDA moderate disease activity (10 < CDAI ≤ 22), HAD high disease activity (CDAI > 22)Back to article page